BSG and breast carcinoma: In this study, we have demonstrated the ability of the new anti-EMMPRIN monoclonal antibody hMR18-mAb to inhibit the activation of the EMT program and induce dormancy in three tumor cell lines of breast cancer and oral squamous cell carcinoma (OSCC).